Mirum Pharmaceuticals (NASDAQ:MIRM) COO Sells $302,325.17 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich sold 3,143 shares of the stock in a transaction on Monday, January 26th. The shares were sold at an average price of $96.19, for a total value of $302,325.17. Following the sale, the chief operating officer owned 23,286 shares in the company, valued at $2,239,880.34. The trade was a 11.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Peter Radovich also recently made the following trade(s):

• On Thursday, January 22nd, Peter Radovich sold 2,382 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $93.33, for a total transaction of $222,312.06.

Mirum Pharmaceuticals Stock Up 2.4%

NASDAQ MIRM traded up $2.35 during midday trading on Tuesday, hitting $99.27. 679,931 shares of the company traded hands, compared to its average volume of 877,176. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.31 and a quick ratio of 3.16. The company has a market cap of $5.10 billion, a PE ratio of -115.43 and a beta of 0.48. Mirum Pharmaceuticals, Inc. has a 52 week low of $36.88 and a 52 week high of $99.44. The company’s 50-day simple moving average is $77.82 and its 200-day simple moving average is $71.21.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.15. The business had revenue of $133.01 million during the quarter, compared to analysts’ expectations of $130.11 million. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The company’s revenue for the quarter was up 47.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.30) EPS. As a group, equities research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. MCF Advisors LLC increased its stake in shares of Mirum Pharmaceuticals by 76.4% in the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after buying an additional 185 shares during the period. Quantbot Technologies LP acquired a new stake in shares of Mirum Pharmaceuticals in the 3rd quarter worth about $33,000. Comerica Bank boosted its position in shares of Mirum Pharmaceuticals by 45.1% during the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after buying an additional 278 shares during the last quarter. Quarry LP bought a new stake in shares of Mirum Pharmaceuticals in the 3rd quarter worth $41,000. Finally, CWM LLC lifted its position in shares of Mirum Pharmaceuticals by 30.8% during the 3rd quarter. CWM LLC now owns 683 shares of the company’s stock worth $50,000 after buying an additional 161 shares in the last quarter.

Analysts Set New Price Targets

MIRM has been the topic of several analyst reports. JMP Securities set a $95.00 target price on Mirum Pharmaceuticals in a report on Wednesday, November 5th. Citigroup reissued an “outperform” rating on shares of Mirum Pharmaceuticals in a research note on Friday, December 19th. Cantor Fitzgerald reissued an “overweight” rating and set a $130.00 price objective on shares of Mirum Pharmaceuticals in a report on Monday, December 8th. Wall Street Zen raised Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 17th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Mirum Pharmaceuticals in a research note on Monday, January 12th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Mirum Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $104.92.

More Mirum Pharmaceuticals News

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Large director purchase — Director Patrick J. Heron bought 131,425 shares at ~$68.48 (Jan 23), increasing his ownership ~40%, signaling strong insider conviction. SEC Filing – Heron Form 4
• Positive Sentiment: Price-target upgrade / bullish analyst note — HC Wainwright raised its price target to $130 and kept a Buy rating, issuing a very bullish long?range EPS view (FY2030 EPS est. $6.16). That upgrade and forecast materially boosts upside expectations. The Fly – HC Wainwright Upgrade
• Positive Sentiment: Acquisition closed — Mirum completed the acquisition of Bluejay Therapeutics, expanding its rare?disease portfolio and reinforcing growth/synergy narratives that investors favor in biotech M&A. Yahoo Finance – Bluejay Acquisition
• Positive Sentiment: Momentum / new 52?week high after upgrades — The stock hit a fresh 52?week high following analyst upgrades and the above news, reinforcing momentum trading and positive sentiment among investors. American Banking News – 52?Week High
• Negative Sentiment: Executive selling — Several senior executives sold shares on Jan 26 (CEO Christopher Peetz sold 6,831 shares; COO Peter Radovich, CFO Eric Bjerkholt, SVP Jolanda Howe also sold smaller amounts). While transactions appear modest relative to market cap and include routine diversification, they can trigger short?term selling pressure or worry some investors. SEC filings: CEO CEO Form 4, COO COO Form 4, CFO CFO Form 4, SVP SVP Form 4. Also summarized in a media note on insider selling: American Banking News – Insider Selling

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.